Form 4 for DMAC DiaMedica Therapeutics Inc.
Accepted 2023-11-16 00:00:00 ET · period of report 2023-11-16 · accession 0001235802-23-000111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-16 | 2023-11-16 | DMAC | Wambeke David J. | Chief Business Off | P - Purchase | $2.46 | +20.0K | 527.1K | +4% | +$49.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Shares, no par value per share | 2023-11-16 | P | A | 20,000 | $2.46 | 527,114 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.49, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. |